Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
PROBE
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- NCT04510597 ↗
- Recruiting
- SWOG Cancer Research Network
- Focused
We haven't built an HCP commentary report on PROBE yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PROBE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Cytoreductive Nephrectomy; Active Comparator
- Arms
- Arm 1: Continued Systemic Therapy Only · Active comparator
- Arm 2: Nephrectomy and Continued Systemic Therapy · Experimental
- Enrollment
- 364 (estimated)
- Primary outcomes
- Overall survival
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Mar 8, 2021
- Primary completion
- Jul 2033 (estimated)
- Results posted
- No
- Registry record
- NCT04510597 · updated Oct 8, 2026
Publications
linked from the registry- Bell H, Cotta BH, Salami SS, Kim H, Vaishampayan U. "PROBE"ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer. Kidney Cancer J. 2022 Mar 15;6(1):3-9. doi: 10.3233/kca-210010. PubMed 35310961
- Kuusk T, Abu-Ghanem Y, Mumtaz F, Powles T, Bex A. Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy. Curr Opin Urol. 2021 May 1;31(3):262-269. doi: 10.1097/MOU.0000000000000868. PubMed 33742979